Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Sight Sciences (SGHT) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Sight Sciences' Gains from Sales and Divestitures rose 3806.19% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 3806.19%. This contributed to the annual value of $1.2 million for FY2024, which is 41163.81% up from last year.
  • As of Q3 2025, Sight Sciences' Gains from Sales and Divestitures stood at $1.2 million, which was up 3806.19% from $874208.0 recorded in Q2 2025.
  • Over the past 5 years, Sight Sciences' Gains from Sales and Divestitures peaked at $1.2 million during Q4 2024, and registered a low of $11028.0 during Q4 2022.
  • For the 4-year period, Sight Sciences' Gains from Sales and Divestitures averaged around $697392.1, with its median value being $874208.0 (2025).
  • Per our database at Business Quant, Sight Sciences' Gains from Sales and Divestitures soared by 210951.22% in 2023 and then skyrocketed by 3806.19% in 2025.
  • Over the past 4 years, Sight Sciences' Gains from Sales and Divestitures (Quarter) stood at $11028.0 in 2022, then skyrocketed by 2109.51% to $243665.0 in 2023, then skyrocketed by 411.64% to $1.2 million in 2024, then fell by 2.19% to $1.2 million in 2025.
  • Its Gains from Sales and Divestitures stands at $1.2 million for Q3 2025, versus $874208.0 for Q2 2025 and $403584.0 for Q1 2025.